{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:58:00Z","timestamp":1732042680965},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,19]]},"DOI":"10.7759\/cureus.37844","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T18:16:35Z","timestamp":1681928195000},"source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Heet N","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Sangurima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maujid Masood","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nency","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Siby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srilakshmi K","family":"Jayaprakasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doju","family":"Cheriachan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S188761","article-title":"Use of levosimendan in acute and advanced heart failure: short review on available real-world data","volume":"15","author":"Pashkovetsky E","year":"2019","unstructured":"Pashkovetsky E, Gupta CA, Aronow WS. Use of levosimendan in acute and advanced heart failure: short review on available real-world data. Ther Clin Risk Manag. 2019, 15:765-72. 10.2147\/TCRM.S188761","journal-title":"Ther Clin Risk Manag"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.889767","article-title":"Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure","volume":"20","author":"Tasal A","year":"2014","unstructured":"Tasal A, Demir M, Kanadasi M, et al.. Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure. Med Sci Monit. 2014, 20:276-82. 10.12659\/MSM.889767","journal-title":"Med Sci Monit"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmu.2017.04.004","article-title":"Levosimendan in acute decompensated heart failure: systematic review and meta-analysis","volume":"19","author":"Cornejo-Avenda\u00f1o J","year":"2017","unstructured":"Cornejo-Avenda\u00f1o J, Azpiri-L\u00f3pez J, and Ram\u00edrez-Rosales A. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Medicina Universitaria. 2017, 19:80-97. 10.1016\/j.rmu.2017.04.004","journal-title":"Medicina Universitaria"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11143997","article-title":"Levosimendan administration may provide more benefit for survival in patients with non-ischemic cardiomyopathy experiencing acute decompensated heart failure","volume":"11","author":"Lee WC","year":"2022","unstructured":"Lee WC, Wu PJ, Fang HY, et al.. Levosimendan administration may provide more benefit for survival in patients with non-ischemic cardiomyopathy experiencing acute decompensated heart failure. J Clin Med. 2022, 11:3997. 10.3390\/jcm11143997","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.05.009","article-title":"The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion","volume":"218","author":"Nieminen MS","year":"2016","unstructured":"Nieminen MS, Buerke M, Cohen-Sol\u00e1l A, et al.. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol. 2016, 218:150-7. 10.1016\/j.ijcard.2016.05.009","journal-title":"Int J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suy039","article-title":"Use of levosimendan in acute heart failure","volume":"20","author":"Harjola VP","year":"2018","unstructured":"Harjola VP, Giannakoulas G, von Lewinski D, et al.. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018, 20:I2-I10. 10.1093\/eurheartj\/suy039","journal-title":"Eur Heart J Suppl"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet J","year":"2018","unstructured":"Com\u00edn-Colet J, Manito N, Segovia-Cubero J, et al.. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018, 20:1128-36. 10.1002\/ejhf.1145","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2019.01.R1","article-title":"Haemodynamic balance in acute and advanced heart failure: an expert perspective on the role of levosimendan","volume":"5","author":"Agostoni P","year":"2019","unstructured":"Agostoni P, Farmakis DT, Garc\u00eda-Pinilla JM, et al.. Haemodynamic balance in acute and advanced heart failure: an expert perspective on the role of levosimendan. Card Fail Rev. 2019, 5:155-61. 10.15420\/cfr.2019.01.R1","journal-title":"Card Fail Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2674-4","article-title":"Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper","volume":"23","author":"Cholley B","year":"2019","unstructured":"Cholley B, Levy B, Fellahi JL, Longrois D, Amour J, Ouattara A, Mebazaa A. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care. 2019, 23:385. 10.1186\/s13054-019-2674-4","journal-title":"Crit Care"},{"key":"ref10","article-title":"Levosimendan: current data, clinical use and future development","volume":"5","author":"Nieminen MS","year":"2013","unstructured":"Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M, Pollesello P. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013, 5:227-45.","journal-title":"Heart Lung Vessel"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000533","article-title":"Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications","volume":"71","author":"Altenberger J","year":"2018","unstructured":"Altenberger J, Gustafsson F, Harjola VP, et al.. Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications. J Cardiovasc Pharmacol. 2018, 71:129-36. 10.1097\/FJC.0000000000000533","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6515\/ACS.201911_35(6).20190327A","article-title":"Effects of levosimendan on right ventricular function in patients with acute decompensated heart failure","volume":"35","author":"Wang YB","year":"2019","unstructured":"Wang YB, Hao GZ, Jiang YF, et al.. Effects of levosimendan on right ventricular function in patients with acute decompensated heart failure. Acta Cardiol Sin. 2019, 35:585-91. 10.6515\/ACS.201911_35(6).20190327A","journal-title":"Acta Cardiol Sin"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0300060516655244","article-title":"Intermittent levosimendan infusions in advanced heart failure: a real world experience","volume":"45","author":"Ortis B","year":"2017","unstructured":"Ortis B, Villani A, Oldani M, et al.. Intermittent levosimendan infusions in advanced heart failure: a real world experience. J Int Med Res. 2017, 45:361-71. 10.1177\/0300060516655244","journal-title":"J Int Med Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.07.202","article-title":"Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper","volume":"222","author":"Farmakis D","year":"2016","unstructured":"Farmakis D, Alvarez J, Gal TB, et al.. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016, 222:303-12. 10.1016\/j.ijcard.2016.07.202","journal-title":"Int J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13670","article-title":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez MJ","year":"2021","unstructured":"Garc\u00eda-Gonz\u00e1lez MJ, Aldea Perona A, Lara Padron A, et al.. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC Heart Fail. 2021, 8:4820-31. 10.1002\/ehf2.13670","journal-title":"ESC Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-018-6838-2","article-title":"Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application","volume":"32","author":"Bouchez S","year":"2018","unstructured":"Bouchez S, Fedele F, Giannakoulas G, et al.. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018, 32:617-24. 10.1007\/s10557-018-6838-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000636","article-title":"Use of levosimendan in intensive care unit settings: an opinion paper","volume":"73","author":"Herpain A","year":"2019","unstructured":"Herpain A, Bouchez S, Girardis M, et al.. Use of levosimendan in intensive care unit settings: an opinion paper. J Cardiovasc Pharmacol. 2019, 73:3-14. 10.1097\/FJC.0000000000000636","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009669.pub4","article-title":"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome","volume":"11","author":"Uhlig K","year":"2020","unstructured":"Uhlig K, Efremov L, Tongers J, Frantz S, Mikolajczyk R, Sedding D, Schumann J. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2020, 11:CD009669. 10.1002\/14651858.CD009669.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03317-5","article-title":"The effect of levosimendan on right ventricular function in patients with heart dysfunction: a systematic review and meta-analysis","volume":"11","author":"Hu Y","year":"2021","unstructured":"Hu Y, Wei Z, Zhang C, Lu C, Zeng Z. The effect of levosimendan on right ventricular function in patients with heart dysfunction: a systematic review and meta-analysis. Sci Rep. 2021, 11:24097. 10.1038\/s41598-021-03317-5","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12272","article-title":"Haemodynamic effects of levosimendan in advanced but stable chronic heart failure","volume":"5","author":"Najjar E","year":"2018","unstructured":"Najjar E, St\u00e5lhberg M, Hage C, Ottenblad E, Manouras A, Haugen L\u00f6fman I, Lund LH. Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. ESC Heart Fail. 2018, 5:302-8. 10.1002\/ehf2.12272","journal-title":"ESC Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-03746-2_31","article-title":"Inotropic support in the treatment of septic myocardial dysfunction: pathophysiological implications supporting the use of levosimendan","volume":"2014","author":"Morelli A","year":"2014","unstructured":"Morelli A, Passariello M, Singer M. Inotropic support in the treatment of septic myocardial dysfunction: pathophysiological implications supporting the use of levosimendan. Annual Update in Intensive Care and Emergency Medicine 2014. 2014, 2014:407-19. 10.1007\/978-3-319-03746-2_31","journal-title":"Annual Update in Intensive Care and Emergency Medicine 2014"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi875","article-title":"Evidence-based use of levosimendan in different clinical settings","volume":"27","author":"De Luca L","year":"2006","unstructured":"De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006, 27:1908-20. 10.1093\/eurheartj\/ehi875","journal-title":"Eur Heart J"},{"key":"ref23","article-title":"Levosimendan: studies on its mechanisms of action and beyond","author":"Kaheinen P","year":"2009","unstructured":"Kaheinen P. Levosimendan: studies on its mechanisms of action and beyond. Helsinki University Print, 2009."},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.2147\/vhrm.2006.2.4.389","article-title":"A review of levosimendan in the treatment of heart failure","volume":"2","author":"Kasikcioglu HA","year":"2006","unstructured":"Kasikcioglu HA, Cam N. A review of levosimendan in the treatment of heart failure. Vasc Health Risk Manag. 2006, 2:389-400.","journal-title":"Vasc Health Risk Manag"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2021.1905520","article-title":"An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety","volume":"19","author":"Heringlake M","year":"2021","unstructured":"Heringlake M, Alvarez J, Bettex D, et al.. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev Cardiovasc Ther. 2021, 19:325-35. 10.1080\/14779072.2021.1905520","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S295214","article-title":"Evidence and current use of levosimendan in the treatment of heart failure: filling the gap","volume":"15","author":"Conti N","year":"2021","unstructured":"Conti N, Gatti M, Raschi E, Diemberger I, Potena L. Evidence and current use of levosimendan in the treatment of heart failure: filling the gap. Drug Des Devel Ther. 2021, 15:3391-409. 10.2147\/DDDT.S295214","journal-title":"Drug Des Devel Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term\u00a0clinical course of patients with acutely\u00a0decompensated heart failure","volume":"1","author":"Packer M","year":"2013","unstructured":"Packer M, Colucci W, Fisher L, et al.. Effect of levosimendan on the short-term\u00a0clinical course of patients with acutely\u00a0decompensated heart failure. JACC Heart Fail. 2013, 1:103-11. 10.1016\/j.jchf.2012.12.004","journal-title":"JACC Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev VS","year":"2002","unstructured":"Moiseyev VS, P\u00f5der P, Andrejevs N, et al.. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002, 23:1422-32. 10.1053\/euhj.2001.3158","journal-title":"Eur Heart J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-005-2619-z","article-title":"Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression","volume":"31","author":"Morelli A","year":"2005","unstructured":"Morelli A, De Castro S, Teboul JL, et al.. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005, 31:638-44. 10.1007\/s00134-005-2619-z","journal-title":"Intensive Care Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/145721-therapeutic-development-of-levosimendan-in-acute-and-advanced-heart-failure-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:57Z","timestamp":1707508797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/145721-therapeutic-development-of-levosimendan-in-acute-and-advanced-heart-failure-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.37844","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}